期刊
CNS NEUROSCIENCE & THERAPEUTICS
卷 21, 期 5, 页码 417-424出版社
WILEY
DOI: 10.1111/cns.12372
关键词
Alpha-aminobutyric acid; Ethanolamine; Glutamic acid; Metabolomics; Selective serotonin reuptake inhibitor
资金
- Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A110339]
- Korea Health Promotion Institute [A110339] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
AimsAmino acids are important body metabolites and seem to be helpful for understanding pathogenesis and predicting therapeutic response in major depressive disorder (MDD). We performed amino acid profiling to discover potential biomarkers in major depressive patients treated with selective serotonin reuptake inhibitors (SSRIs). MethodsAmino acid profiling using aTRAQ kits for Amino Acid Analysis in Physiological Fluids on a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system was performed on 158 specimens at baseline and at 6weeks after the initiation of SSRI treatment for 68 patients with MDD and from 22 healthy controls. ResultsBaseline alpha-aminobutyric acid (ABA) discriminated the patients according to the therapeutic response. Plasma glutamic acid concentration and glutamine/glutamic acid ratio were different between before and after SSRI treatment only in the response group. Comparing patients with MDD with healthy controls, alterations of ten amino acids, including alanine, beta-alanine, beta-aminoisobutyric acid, cystathionine, ethanolamine, glutamic acid, homocystine, methionine, O-phospho-L-serine, and sarcosine, were observed in MDD. ConclusionMetabolism of amino acids, including ABA and glutamic acid, has the potential to contribute to understandings of pathogenesis and predictions of therapeutic response in MDD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据